Apart from NF2 alterations in sporadic meningiomas, various oncogenic mutations in KLF4, SMO, TRAF7, PIK3CA, AKT1 and POLR2A are also found to be clinically actionable genetic events in meningiomas (3–5). This evidence concerns the gene NF2 and meningioma.